{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:49:21Z","timestamp":1779904161035,"version":"3.53.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MedScience"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>N<\/jats:italic>\n                    <jats:sup>6<\/jats:sup>\n                    -methyladenosine (m\n                    <jats:sup>6<\/jats:sup>\n                    A) RNA modification has emerged as a pivotal epitranscriptomic mark shaping RNA metabolism and cellular programs. Among the diverse m\n                    <jats:sup>6<\/jats:sup>\n                    A reader proteins, YTHDF2 has garnered significant attention as a key regulator of RNA stability. Recent studies highlight the multifaceted roles of YTHDF2 in orchestrating hematopoietic stem cell self-renewal and differentiation, fine-tuning immune cell development and function, and modulating tumor-immune interactions within the tumor microenvironment. YTHDF2 has also been shown to function as a reader for RNA 5-methylcytosine (m\n                    <jats:sup>5<\/jats:sup>\n                    C) modification. By linking m\n                    <jats:sup>6<\/jats:sup>\n                    A- and\/or m\n                    <jats:sup>5<\/jats:sup>\n                    C-dependent RNA dynamics to hemato-immune homeostasis, YTHDF2 functions as a central epitranscriptomic integrator linking intrinsic genetic programs to developmental and environmental cues. Here, we summarize current advances in understanding YTHDF2-mediated RNA regulation across physiological and pathological contexts, discuss its potential as a therapeutic target in immune-related diseases and cancers, and highlight future directions in the field.\n                  <\/jats:p>","DOI":"10.1007\/s11684-026-1203-5","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:11:19Z","timestamp":1775034679000},"page":"59-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging role of RNA modification reader YTHDF2 in hematopoiesis, immunity, and cancer"],"prefix":"10.1007","volume":"20","author":[{"given":"Xin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songqi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoubao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"7","key":"1203_CR1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell 2017; 169(7): 1187\u20131200","journal-title":"Cell"},{"key":"1203_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-3-031-45654-1_3","volume":"190","author":"S Ma","year":"2023","unstructured":"Ma S, Barr T, Yu J. Recent advances of RNA m6A modifications in cancer immunoediting and immunotherapy. Cancer Treat Res 2023; 190: 49\u201394","journal-title":"Cancer Treat Res"},{"issue":"4","key":"1203_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.molcel.2019.04.025","volume":"74","author":"H Shi","year":"2019","unstructured":"Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell 2019; 74(4): 640\u2013650","journal-title":"Mol Cell"},{"issue":"1","key":"1203_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrm.2016.132","volume":"18","author":"BS Zhao","year":"2017","unstructured":"Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol 2017; 18(1): 31\u201342","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"1203_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41422-018-0040-8","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res 2018; 28(6): 616\u2013624","journal-title":"Cell Res"},{"issue":"2","key":"1203_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41375-024-02451-z","volume":"39","author":"Y Yang","year":"2025","unstructured":"Yang Y, Hsu PJ, Chen YS, Yang YG. YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1\/me3 epigenetic axis. Leukemia 2025; 39(2): 308\u2013322","journal-title":"Leukemia"},{"issue":"6","key":"1203_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.molmed.2023.03.005","volume":"29","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang D, Liu T, Chen J, Yu J, Yi P. N6-methyladenosine-mediated gene regulation and therapeutic implications. Trends Mol Med 2023; 29(6): 454\u2013467","journal-title":"Trends Mol Med"},{"issue":"8","key":"1203_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1182\/blood.2019004263","volume":"138","author":"Y Qing","year":"2021","unstructured":"Qing Y, Su R, Chen J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood 2021; 138(8): 637\u2013648","journal-title":"Blood"},{"issue":"6","key":"1203_CR9","doi-asserted-by":"publisher","first-page":"e1666","DOI":"10.1002\/ctm2.1666","volume":"14","author":"M Chen","year":"2024","unstructured":"Chen M, Chen Y, Wang K, Deng X, Chen J. Non-m6A RNA modifications in haematological malignancies. Clin Transl Med 2024; 14(6): e1666","journal-title":"Clin Transl Med"},{"issue":"2","key":"1203_CR10","doi-asserted-by":"publisher","first-page":"100023","DOI":"10.1016\/j.clnves.2025.100023","volume":"1","author":"L Zhang","year":"2025","unstructured":"Zhang L, Lou Y, Li W, Guo H, Truong Nguyen LX, Chen Z. RNA m6A modification: a key regulator in normal and malignant processes. Cell Investig 2025; 1(2): 100023","journal-title":"Cell Investig"},{"key":"1203_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.semcancer.2022.03.025","volume":"86","author":"W Li","year":"2022","unstructured":"Li W, Deng X, Chen J. RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer. Semin Cancer Biol 2022; 86(Pt 2): 664\u2013677","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1203_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12943-022-01558-0","volume":"21","author":"X Li","year":"2022","unstructured":"Li X, Ma S, Deng Y, Yi P, Yu J. Targeting the RNA m6A modification for cancer immunotherapy. Mol Cancer 2022; 21(1): 76","journal-title":"Mol Cancer"},{"issue":"8","key":"1203_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","volume":"20","author":"X Deng","year":"2023","unstructured":"Deng X, Qing Y, Horne D, Huang H, Chen J. The roles and implications of RNA m6A modification in cancer. Nat Rev Clin Oncol 2023; 20(8): 507\u2013526","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1203_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1566523222666220830150446","volume":"23","author":"Y Li","year":"2023","unstructured":"Li Y, Huang H, Wu S, Zhou Y, Huang T, Jiang J. The role of RNA m6A modification in cancer glycolytic reprogramming. Curr Gene Ther 2023; 23(1): 51\u201359","journal-title":"Curr Gene Ther"},{"issue":"3","key":"1203_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/0113892029296712240405053201","volume":"25","author":"R Mehmood","year":"2024","unstructured":"Mehmood R. Ramifications of m6A modification on ncRNAs in cancer. Curr Genomics 2024; 25(3): 158\u2013170","journal-title":"Curr Genomics"},{"issue":"7481","key":"1203_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, Ren B, Pan T, He C. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 2014; 505(7481): 117\u2013120","journal-title":"Nature"},{"issue":"6","key":"1203_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.it.2025.04.003","volume":"46","author":"S Xiao","year":"2025","unstructured":"Xiao S, Duan S, Caligiuri MA, Ma S, Yu J. YTHDF2: a key RNA reader and antitumor target. Trends Immunol 2025; 46(6): 485\u2013498","journal-title":"Trends Immunol"},{"issue":"2","key":"1203_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cell.2024.11.007","volume":"188","author":"S Xiao","year":"2025","unstructured":"Xiao S, Duan S, Caligiuri MA, Ma S, Yu J. YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell 2025; 188(2): 331\u2013351.e30","journal-title":"Cell"},{"issue":"2","key":"1203_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41590-022-01398-6","volume":"24","author":"S Ma","year":"2023","unstructured":"Ma S, Sun B, Duan S, Han J, Barr T, Zhang J, Bissonnette MB, Kortylewski M, He C, Chen J, Caligiuri MA, Yu J. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells. Nat Immunol 2023; 24(2): 255\u2013266","journal-title":"Nat Immunol"},{"issue":"95","key":"1203_CR20","doi-asserted-by":"publisher","first-page":"eadl2171","DOI":"10.1126\/sciimmunol.adl2171","volume":"9","author":"S Xiao","year":"2024","unstructured":"Xiao S, Ma S, Sun B, Pu W, Duan S, Han J, Hong Y, Zhang J, Peng Y, He C, Yi P, Caligiuri MA, Yu J. The tumor-intrinsic role of the m6A reader YTHDF2 in regulating immune evasion. Sci Immunol 2024; 9(95): eadl2171","journal-title":"Sci Immunol"},{"issue":"7671","key":"1203_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature23883","volume":"549","author":"C Zhang","year":"2017","unstructured":"Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, Lv J, Heng J, Ding Y, Xue Y, Lu X, Xiao W, Yang YG, Liu F. m6A modulates haematopoietic stem and progenitor cell specification. Nature 2017; 549(7671): 273\u2013276","journal-title":"Nature"},{"issue":"1","key":"1203_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12943-019-1082-3","volume":"18","author":"J Hou","year":"2019","unstructured":"Hou J, Zhang H, Liu J, Zhao Z, Wang J, Lu Z, Hu B, Zhou J, Zhao Z, Feng M, Zhang H, Shen B, Huang X, Sun B, Smyth MJ, He C, Xia Q. YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Mol Cancer 2019; 18(1): 163","journal-title":"Mol Cancer"},{"issue":"1","key":"1203_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.stem.2019.03.021","volume":"25","author":"J Paris","year":"2019","unstructured":"Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, Mapperley C, Lawson H, Wotherspoon DA, Sepulveda C, Vukovic M, Allen L, Sarapuu A, Tavosanis A, Guitart AV, Villacreces A, Much C, Choe J, Azar A, van de Lagemaat LN, Vernimmen D, Nehme A, Mazurier F, Somervaille TCP, Gregory RI, O\u2019Carroll D, Kranc KR. Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell 2019; 25(1): 137\u2013148.e6","journal-title":"Cell Stem Cell"},{"issue":"2","key":"1203_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41590-018-0275-z","volume":"20","author":"R Winkler","year":"2019","unstructured":"Winkler R, Gillis E, Lasman L, Safra M, Geula S, Soyris C, Nachshon A, Tai-Schmiedel J, Friedman N, Le-Trilling VTK, Trilling M, Mandelboim M, Hanna JH, Schwartz S, Stern-Ginossar N. m6A modification controls the innate immune response to infection by targeting type I interferons. Nat Immunol 2019; 20(2): 173\u2013182","journal-title":"Nat Immunol"},{"issue":"1","key":"1203_CR25","doi-asserted-by":"publisher","first-page":"100008","DOI":"10.1016\/j.clnves.2025.100008","volume":"1","author":"L Zhang","year":"2025","unstructured":"Zhang L, Chen C, Feng J, Zhang H, Nguyen LXT, Chen Z. The role of YTHDF2 in anti-tumor immunity. Cell Investig 2025; 1(1): 100008","journal-title":"Cell Investig"},{"issue":"6","key":"1203_CR26","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","volume":"161","author":"X Wang","year":"2015","unstructured":"Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H, He C. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 2015; 161(6): 1388\u20131399","journal-title":"Cell"},{"issue":"3","key":"1203_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/cr.2017.15","volume":"27","author":"H Shi","year":"2017","unstructured":"Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, He C. YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Res 2017; 27(3): 315\u2013328","journal-title":"Cell Res"},{"issue":"19\u201320","key":"1203_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1101\/gad.340695.120","volume":"34","author":"L Lasman","year":"2020","unstructured":"Lasman L, Krupalnik V, Viukov S, Mor N, Aguilera-Castrejon A, Schneir D, Bayerl J, Mizrahi O, Peles S, Tawil S, Sathe S, Nachshon A, Shani T, Zerbib M, Kilimnik I, Aigner S, Shankar A, Mueller JR, Schwartz S, Stern-Ginossar N, Yeo GW, Geula S, Novershtern N, Hanna JH. Context-dependent functional compensation between Ythdf m6A reader proteins. Genes Dev 2020; 34(19\u201320): 1373\u20131391","journal-title":"Genes Dev"},{"issue":"1","key":"1203_CR29","doi-asserted-by":"publisher","first-page":"12626","DOI":"10.1038\/ncomms12626","volume":"7","author":"H Du","year":"2016","unstructured":"Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, Ma J, Wu L. YTHDF2 destabilizes m6A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun 2016; 7(1): 12626","journal-title":"Nat Commun"},{"issue":"3","key":"1203_CR30","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.molcel.2019.02.034","volume":"74","author":"OH Park","year":"2019","unstructured":"Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, Kim YK. Endoribonucleolytic cleavage of m6A-containing RNAs by RNase P\/MRP complex. Mol Cell 2019; 74(3): 494\u2013507.e8","journal-title":"Mol Cell"},{"issue":"1","key":"1203_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-020-01263-w","volume":"20","author":"P Nombela","year":"2021","unstructured":"Nombela P, Miguel-L\u00f3pez B, Blanco S. The role of m6A, m5C and \u03a8 RNA modifications in cancer: novel therapeutic opportunities. Mol Cancer 2021; 20(1): 18","journal-title":"Mol Cancer"},{"issue":"5","key":"1203_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1261\/rna.079982.124","volume":"30","author":"M Guarnacci","year":"2024","unstructured":"Guarnacci M, Preiss T. The je ne sais quoi of 5-methylcytosine in messenger RNA. RNA 2024; 30(5): 560\u2013569","journal-title":"RNA"},{"issue":"6","key":"1203_CR33","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.molcel.2019.06.033","volume":"75","author":"Y Yang","year":"2019","unstructured":"Yang Y, Wang L, Han X, Yang WL, Zhang M, Ma HL, Sun BF, Li A, Xia J, Chen J, Heng J, Wu B, Chen YS, Xu JW, Yang X, Yao H, Sun J, Lyu C, Wang HL, Huang Y, Sun YP, Zhao YL, Meng A, Ma J, Liu F, Yang YG. RNA 5-Methylcytosine facilitates the maternal-to-zygotic transition by preventing maternal mRNA decay. Mol Cell 2019; 75(6): 1188\u20131202.e11","journal-title":"Mol Cell"},{"issue":"12","key":"1203_CR34","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.molcel.2025.05.015","volume":"85","author":"T Liu","year":"2025","unstructured":"Liu T, Yang D, Wei Q, Wang Y, Tian L, Liu X, Yang Y, Luo Q, Xu J, Liu Y, Yang C, Zuo X, Luo F, Luo X, Zhao H, Li L, Xu J, Yu J, Ma S, Yu J, Yi P. The RNA-stability-independent role of the RNA m6A reader YTHDF2 in promoting protein translation to confer tumor chemotherapy resistance. Mol Cell 2025; 85(12): 2320\u20132336.e9","journal-title":"Mol Cell"},{"issue":"7285","key":"1203_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature08761","volume":"464","author":"K Kissa","year":"2010","unstructured":"Kissa K, Herbomel P. Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 2010; 464(7285): 112\u2013115","journal-title":"Nature"},{"issue":"7285","key":"1203_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08738","volume":"464","author":"JY Bertrand","year":"2010","unstructured":"Bertrand JY, Chi NC, Santoso B, Teng S, Stainier DYR, Traver D. Haematopoietic stem cells derive directly from aortic endothelium during development. Nature 2010; 464(7285): 108\u2013111","journal-title":"Nature"},{"issue":"1","key":"1203_CR37","doi-asserted-by":"publisher","first-page":"7739","DOI":"10.1038\/ncomms8739","volume":"6","author":"CO Lizama","year":"2015","unstructured":"Lizama CO, Hawkins JS, Schmitt CE, Bos FL, Zape JP, Cautivo KM, Borges Pinto H, Rhyner AM, Yu H, Donohoe ME, Wythe JD, Zovein AC. Repression of arterial genes in hemogenic endothelium is sufficient for haematopoietic fate acquisition. Nat Commun 2015; 6(1): 7739","journal-title":"Nat Commun"},{"issue":"1","key":"1203_CR38","doi-asserted-by":"publisher","first-page":"8510","DOI":"10.1038\/ncomms9510","volume":"6","author":"L Gama-Norton","year":"2015","unstructured":"Gama-Norton L, Ferrando E, Ruiz-Herguido C, Liu Z, Guiu J, Islam ABMMK, Lee SU, Yan M, Guidos CJ, L\u00f3pez-Bigas N, Maeda T, Espinosa L, Kopan R, Bigas A. Notch signal strength controls cell fate in the haemogenic endothelium. Nat Commun 2015; 6(1): 8510","journal-title":"Nat Commun"},{"issue":"10","key":"1203_CR39","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/cr.2015.109","volume":"25","author":"P Zhang","year":"2015","unstructured":"Zhang P, He Q, Chen D, Liu W, Wang L, Zhang C, Ma D, Li W, Liu B, Liu F. G protein-coupled receptor 183 facilitates endothelial-to-hematopoietic transition via Notch1 inhibition. Cell Res 2015; 25(10): 1093\u20131107","journal-title":"Cell Res"},{"issue":"9","key":"1203_CR40","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41422-018-0072-0","volume":"28","author":"Z Li","year":"2018","unstructured":"Li Z, Qian P, Shao W, Shi H, He XC, Gogol M, Yu Z, Wang Y, Qi M, Zhu Y, Perry JM, Zhang K, Tao F, Zhou K, Hu D, Han Y, Zhao C, Alexander R, Xu H, Chen S, Peak A, Hall K, Peterson M, Perera A, Haug JS, Parmely T, Li H, Shen B, Zeitlinger J, He C, Li L. Suppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion. Cell Res 2018; 28(9): 904\u2013917","journal-title":"Cell Res"},{"issue":"10","key":"1203_CR41","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41422-018-0082-y","volume":"28","author":"H Wang","year":"2018","unstructured":"Wang H, Zuo H, Liu J, Wen F, Gao Y, Zhu X, Liu B, Xiao F, Wang W, Huang G, Shen B, Ju Z. Loss of YTHDF2-mediated m6A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration. Cell Res 2018; 28(10): 1035\u20131038","journal-title":"Cell Res"},{"issue":"3","key":"1203_CR42","doi-asserted-by":"publisher","first-page":"e20200829","DOI":"10.1084\/jem.20200829","volume":"218","author":"C Mapperley","year":"2021","unstructured":"Mapperley C, van de Lagemaat LN, Lawson H, Tavosanis A, Paris J, Campos J, Wotherspoon D, Durko J, Sarapuu A, Choe J, Ivanova I, Krause DS, von Kriegsheim A, Much C, Morgan M, Gregory RI, Mead AJ, O\u2019Carroll D, Kranc KR. The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function. J Exp Med 2021; 218(3): e20200829","journal-title":"J Exp Med"},{"issue":"1","key":"1203_CR43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","volume":"19","author":"RR Hardy","year":"2001","unstructured":"Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol 2001; 19(1): 595\u2013621","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1203_CR44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","volume":"30","author":"GD Victora","year":"2012","unstructured":"Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol 2012; 30(1): 429\u2013457","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"1203_CR45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/ni.2210","volume":"13","author":"K Ochiai","year":"2012","unstructured":"Ochiai K, Maienschein-Cline M, Mandal M, Triggs JR, Bertolino E, Sciammas R, Dinner AR, Clark MR, Singh H. A self-reinforcing regulatory network triggered by limiting IL-7 activates pre-BCR signaling and differentiation. Nat Immunol 2012; 13(3): 300\u2013307","journal-title":"Nat Immunol"},{"issue":"13","key":"1203_CR46","doi-asserted-by":"publisher","first-page":"107819","DOI":"10.1016\/j.celrep.2020.107819","volume":"31","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Zhang L, Cui XL, Yu X, Hsu PJ, Lyu R, Tan H, Mandal M, Zhang M, Sun HL, Sanchez Castillo A, Peng J, Clark MR, He C, Huang H. Control of early B cell development by the RNA N6-methyladenosine methylation. Cell Rep 2020; 31(13): 107819","journal-title":"Cell Rep"},{"issue":"5","key":"1203_CR47","doi-asserted-by":"publisher","first-page":"110778","DOI":"10.1016\/j.celrep.2022.110778","volume":"39","author":"A Grenov","year":"2022","unstructured":"Grenov A, Hezroni H, Lasman L, Hanna JH, Shulman Z. YTHDF2 suppresses the plasmablast genetic program and promotes germinal center formation. Cell Rep 2022; 39(5): 110778","journal-title":"Cell Rep"},{"issue":"11","key":"1203_CR48","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","volume":"18","author":"L Chiossone","year":"2018","unstructured":"Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 2018; 18(11): 671\u2013688","journal-title":"Nat Rev Immunol"},{"issue":"6013","key":"1203_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331(6013): 44\u201349","journal-title":"Science"},{"issue":"20","key":"1203_CR50","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1158\/0008-5472.CAN-23-1097","volume":"83","author":"S Ma","year":"2023","unstructured":"Ma S, Caligiuri MA, Yu J. Harnessing natural killer cells for lung cancer therapy. Cancer Res 2023; 83(20): 3327\u20133339","journal-title":"Cancer Res"},{"issue":"7","key":"1203_CR51","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/jimmun\/vkaf036","volume":"214","author":"S Ma","year":"2025","unstructured":"Ma S, Yu J, Caligiuri MA. Natural killer cell-based immunotherapy for cancer. J Immunol 2025; 214(7): 1444\u20131456","journal-title":"J Immunol"},{"issue":"9","key":"1203_CR52","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri2154","volume":"7","author":"ND Huntington","year":"2007","unstructured":"Huntington ND, Vosshenrich CAJ, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007; 7(9): 703\u2013714","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1203_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2011.11.016","volume":"36","author":"SM Gordon","year":"2012","unstructured":"Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, Lindsten T, Reiner SL. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012; 36(1): 55\u201367","journal-title":"Immunity"},{"issue":"10","key":"1203_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma S, Caligiuri MA, Yu J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol 2022; 43(10): 833\u2013847","journal-title":"Trends Immunol"},{"issue":"5","key":"1203_CR55","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/CCO.0000000000000968","volume":"35","author":"M Sayegh","year":"2023","unstructured":"Sayegh M, Ma S, Yu J. Application of natural killer immunotherapy in blood cancers and solid tumors. Curr Opin Oncol 2023; 35(5): 446\u2013452","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"1203_CR56","doi-asserted-by":"publisher","first-page":"e20210279","DOI":"10.1084\/jem.20210279","volume":"218","author":"S Ma","year":"2021","unstructured":"Ma S, Yan J, Barr T, Zhang J, Chen Z, Wang LS, Sun JC, Chen J, Caligiuri MA, Yu J. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity. J Exp Med 2021; 218(8): e20210279","journal-title":"J Exp Med"},{"key":"1203_CR57","doi-asserted-by":"publisher","first-page":"1440308","DOI":"10.3389\/fimmu.2024.1440308","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Wang Y, Cai L, Huang S. SMAD4 enhances the cytotoxic efficacy of human NK cells against colorectal cancer cells via the m6A reader YTHDF2. Front Immunol 2024; 15: 1440308","journal-title":"Front Immunol"},{"issue":"5","key":"1203_CR58","doi-asserted-by":"publisher","first-page":"e18106","DOI":"10.1111\/jcmm.18106","volume":"28","author":"M Wei","year":"2024","unstructured":"Wei M, Lu L, Ma J, Luo Z, Tan X, Wang J. LINC00707 impairs the natural killer cell antitumour activity in hepatocellular carcinoma through decreasing YTHDF2 stability. J Cell Mol Med 2024; 28(5): e18106","journal-title":"J Cell Mol Med"},{"issue":"11","key":"1203_CR59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nri3073","volume":"11","author":"PJ Murray","year":"2011","unstructured":"Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11(11): 723\u2013737","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1203_CR60","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.it.2010.04.001","volume":"31","author":"S Jaiswal","year":"2010","unstructured":"Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010; 31(6): 212\u2013219","journal-title":"Trends Immunol"},{"issue":"6","key":"1203_CR61","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/ijms20061323","volume":"20","author":"R Yu","year":"2019","unstructured":"Yu R, Li Q, Feng Z, Cai L, Xu Q. m6A reader YTHDF2 regulates LPS-induced inflammatory response. Int J Mol Sci 2019; 20(6): 1323","journal-title":"Int J Mol Sci"},{"key":"1203_CR62","doi-asserted-by":"publisher","first-page":"3153362","DOI":"10.1155\/2022\/3153362","volume":"2022","author":"L Cai","year":"2022","unstructured":"Cai L, Li D, Feng Z, Gu X, Xu Q, Li Q. YTHDF2 regulates macrophage polarization through NF-\u03baB and MAPK signaling pathway inhibition or p53 degradation. Dis Markers 2022; 2022: 3153362","journal-title":"Dis Markers"},{"key":"1203_CR63","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.imlet.2023.11.004","volume":"264","author":"Y Cai","year":"2023","unstructured":"Cai Y, Yu R, Zhang Z, Li D, Yi B, Feng Z, Xu Q. Mettl3\/Ythdf2 regulate macrophage inflammation and ROS generation by controlling Pyk2 mRNA stability. Immunol Lett 2023; 264: 64\u201373","journal-title":"Immunol Lett"},{"issue":"6","key":"1203_CR64","doi-asserted-by":"publisher","first-page":"109902","DOI":"10.1016\/j.isci.2024.109902","volume":"27","author":"H Jin","year":"2024","unstructured":"Jin H, Chen Y, Zhang D, Lin J, Huang S, Wu X, Deng W, Huang J, Yao Y. YTHDF2 favors protumoral macrophage polarization and implies poor survival outcomes in triple negative breast cancer. iScience 2024; 27(6): 109902","journal-title":"iScience"},{"issue":"7","key":"1203_CR65","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1158\/0008-5472.CAN-13-2534","volume":"74","author":"S Ma","year":"2014","unstructured":"Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, Shi L, Wu D, Dong C, Liu H. IL-17A produced by \u03b3\u03b4 T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res 2014; 74(7): 1969\u20131982","journal-title":"Cancer Res"},{"issue":"3","key":"1203_CR66","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 2016; 37(3): 208\u2013220","journal-title":"Trends Immunol"},{"issue":"1","key":"1203_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res 2017; 5(1): 3\u20138","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"1203_CR68","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 2021; 21(8): 485\u2013498","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"1203_CR69","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","volume":"41","author":"L Wang","year":"2023","unstructured":"Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, Chen Y, Wang J, Yang K, Bugno J, Pitroda S, Ding X, Piffko A, Si W, Chen C, Jiang H, Zhou B, Chmura SJ, Luo C, Liang HL, He C, Weichselbaum RR. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell 2023; 41(7): 1294\u20131308.e8","journal-title":"Cancer Cell"},{"issue":"24","key":"1203_CR70","doi-asserted-by":"publisher","first-page":"e172919","DOI":"10.1172\/JCI172919","volume":"133","author":"L Wang","year":"2023","unstructured":"Wang L, Si W, Yu X, Piffko A, Dou X, Ding X, Bugno J, Yang K, Wen C, Zhang L, Chen D, Huang X, Wang J, Arina A, Pitroda S, Chmura SJ, He C, Liang HL, Weichselbaum R. Epitranscriptional regulation of TGF-\u03b2 pseudoreceptor BAMBI by m6A\/YTHDF2 drives extrinsic radioresistance. J Clin Invest 2023; 133(24): e172919","journal-title":"J Clin Invest"},{"key":"1203_CR71","doi-asserted-by":"publisher","first-page":"102993","DOI":"10.1016\/j.jaut.2023.102993","volume":"135","author":"Z Lyu","year":"2023","unstructured":"Lyu Z, Huang B, Zhang J, Qian Q, Pu X, Cui N, Ou Y, Li B, You Z, Lian M, Tang R, Chen W, Zhao Z, Hou J, Gershwin ME, Zhang H, Xia Q, Ma X. Suppression of YTHDF2 attenuates autoimmune hepatitis by expansion of myeloid-derived suppressor cells. J Autoimmun 2023; 135: 102993","journal-title":"J Autoimmun"},{"issue":"11","key":"1203_CR72","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh CH, Lee S, Kwak M, Kim BS, Chung Y. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp Mol Med 2023; 55(11): 2287\u20132299","journal-title":"Exp Mol Med"},{"issue":"6","key":"1203_CR73","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 2019; 234(6): 8509\u20138521","journal-title":"J Cell Physiol"},{"issue":"1","key":"1203_CR74","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol 2019; 37(1): 457\u2013495","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"1203_CR75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15(8): 486\u2013499","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1203_CR76","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015; 36(4): 265\u2013276","journal-title":"Trends Immunol"},{"issue":"6382","key":"1203_CR77","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359(6382): 1350\u20131355","journal-title":"Science"},{"issue":"1","key":"1203_CR78","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.1038\/s41467-024-53997-6","volume":"15","author":"H Zhang","year":"2024","unstructured":"Zhang H, Luo X, Yang W, Wu Z, Zhao Z, Pei X, Zhang X, Chen C, Lei JH, Shi Q, Zhao Q, Chen Y, Wu W, Zeng Z, Ju HQ, Qiu M, Liu J, Shen B, Chen M, Chen J, Deng CX, Xu RH, Hou J. YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity. Nat Commun 2024; 15(1): 9559","journal-title":"Nat Commun"},{"issue":"1","key":"1203_CR79","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","volume":"28","author":"J Zhu","year":"2010","unstructured":"Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28(1): 445\u2013489","journal-title":"Annu Rev Immunol"},{"issue":"15","key":"1203_CR80","doi-asserted-by":"publisher","first-page":"e113126","DOI":"10.15252\/embj.2022113126","volume":"42","author":"L Zhang","year":"2023","unstructured":"Zhang L, Dou X, Zheng Z, Ye C, Lu TX, Liang HL, Wang L, Weichselbaum RR, He C. YTHDF2\/m6A\/NF-\u03baB axis controls anti-tumor immunity by regulating intratumoral Tregs. EMBO J 2023; 42(15): e113126","journal-title":"EMBO J"},{"issue":"9","key":"1203_CR81","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/s41590-025-02235-2","volume":"26","author":"S Xiao","year":"2025","unstructured":"Xiao S, Duan S, Hong Y, Zhang J, Ma S, Caligiuri MA, Yu J. Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy. Nat Immunol 2025; 26(9): 1501\u20131515","journal-title":"Nat Immunol"},{"issue":"5","key":"1203_CR82","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"DI Jang","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci 2021; 22(5): 2719","journal-title":"Int J Mol Sci"},{"key":"1203_CR83","doi-asserted-by":"publisher","first-page":"1042622","DOI":"10.3389\/fimmu.2022.1042622","volume":"13","author":"N Skartsis","year":"2022","unstructured":"Skartsis N, Ferreira LMR, Tang Q. The dichotomous outcomes of TNFa signaling in CD4+ T cells. Front Immunol 2022; 13: 1042622","journal-title":"Front Immunol"},{"issue":"4","key":"1203_CR84","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/jleuko\/qiae087","volume":"116","author":"ECN van Vroonhoven","year":"2024","unstructured":"van Vroonhoven ECN, Picavet LW, Scholman RC, Sijbers LJPM, Kievit CRE, van den Dungen NAM, Mokry M, Evers A, Lebbink RJ, Mocholi E, Coffer PJ, Calis JJA, Vastert SJ, van Loosdregt J. N6-methyladenosine promotes TNF mRNA degradation in CD4+ T lymphocytes. J Leukoc Biol 2024; 116(4): 807\u2013815","journal-title":"J Leukoc Biol"},{"issue":"10","key":"1203_CR85","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.4049\/jimmunol.172.10.6158","volume":"172","author":"N Seki","year":"2004","unstructured":"Seki N, Miyazaki M, Suzuki W, Hayashi K, Arima K, Myburgh E, Izuhara K, Brombacher F, Kubo M. IL-4-induced GATA-3 expression is a time-restricted instruction switch for Th2 cell differentiation. J Immunol 2004; 172(10): 6158\u20136166","journal-title":"J Immunol"},{"issue":"17","key":"1203_CR86","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1093\/emboj\/16.17.5353","volume":"16","author":"A Nakao","year":"1997","unstructured":"Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P. TGF-\u03b2 receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997; 16(17): 5353\u20135362","journal-title":"EMBO J"},{"issue":"4","key":"1203_CR87","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.immuni.2012.01.020","volume":"36","author":"W Elyaman","year":"2012","unstructured":"Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, Radtke F, Yagita H, Khoury SJ. Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity 2012; 36(4): 623\u2013634","journal-title":"Immunity"},{"issue":"5","key":"1203_CR88","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.4049\/jimmunol.1301276","volume":"191","author":"T Tamiya","year":"2013","unstructured":"Tamiya T, Ichiyama K, Kotani H, Fukaya T, Sekiya T, Shichita T, Honma K, Yui K, Matsuyama T, Nakao T, Fukuyama S, Inoue H, Nomura M, Yoshimura A. Smad2\/3 and IRF4 play a cooperative role in IL-9-producing T cell induction. J Immunol 2013; 191(5): 2360\u20132371","journal-title":"J Immunol"},{"issue":"10","key":"1203_CR89","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/ni.3252","volume":"16","author":"H Nakatsukasa","year":"2015","unstructured":"Nakatsukasa H, Zhang D, Maruyama T, Chen H, Cui K, Ishikawa M, Deng L, Zanvit P, Tu E, Jin W, Abbatiello B, Goldberg N, Chen Q, Sun L, Zhao K, Chen W. The DNA-binding inhibitor Id3 regulates IL-9 production in CD4+ T cells. Nat Immunol 2015; 16(10): 1077\u20131084","journal-title":"Nat Immunol"},{"issue":"11","key":"1203_CR90","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1172\/JCI65459","volume":"122","author":"Y Lu","year":"2012","unstructured":"Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, Yang J, Qian J, Yi Q. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012; 122(11): 4160\u20134171","journal-title":"J Clin Invest"},{"issue":"6","key":"1203_CR91","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1073\/pnas.1317431111","volume":"111","author":"Y Lu","year":"2014","unstructured":"Lu Y, Hong B, Li H, Zheng Y, Zhang M, Wang S, Qian J, Yi Q. Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci USA 2014; 111(6): 2265\u20132270","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1203_CR92","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ccell.2018.05.004","volume":"33","author":"Y Lu","year":"2018","unstructured":"Lu Y, Wang Q, Xue G, Bi E, Ma X, Wang A, Qian J, Dong C, Yi Q. Th9 cells represent a unique subset of CD4+ T cells endowed with the ability to eradicate advanced tumors. Cancer Cell 2018; 33(6): 1048\u20131060.e7","journal-title":"Cancer Cell"},{"issue":"1","key":"1203_CR93","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1038\/s41467-020-19672-2","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu L, Bi E, Ma X, Xiong W, Qian J, Ye L, Su P, Wang Q, Xiao L, Yang M, Lu Y, Yi Q. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nat Commun 2020; 11(1): 5902","journal-title":"Nat Commun"},{"issue":"12","key":"1203_CR94","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.ccell.2021.09.011","volume":"39","author":"G Xue","year":"2021","unstructured":"Xue G, Zheng N, Fang J, Jin G, Li X, Dotti G, Yi Q, Lu Y. Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells. Cancer Cell 2021; 39(12): 1610\u20131622.e9","journal-title":"Cancer Cell"},{"issue":"5","key":"1203_CR95","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41419-021-03763-z","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Sheng H, Ma F, Wu Q, Huang J, Chen Q, Sheng L, Zhu X, Zhu X, Xu M. RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1\/Wnt\/\u03b2-catenin signaling. Cell Death Dis 2021; 12(5): 479","journal-title":"Cell Death Dis"},{"issue":"23","key":"1203_CR96","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1038\/s41388-020-1303-7","volume":"39","author":"C Zhang","year":"2020","unstructured":"Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K, Ji F, Ma Z, Hou B, He X. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene 2020; 39(23): 4507\u20134518","journal-title":"Oncogene"},{"issue":"13","key":"1203_CR97","doi-asserted-by":"publisher","first-page":"2307242","DOI":"10.1002\/advs.202307242","volume":"11","author":"J Wen","year":"2024","unstructured":"Wen J, Xue L, Wei Y, Liang J, Jia W, Yong T, Chu L, Li H, Han S, Liao J, Chen Z, Liu Y, Liu Q, Ding Z, Liang H, Gan L, Chen X, Huang Z, Zhang B. YTHDF2 is a therapeutic target for HCC by suppressing immune evasion and angiogenesis through ETV5\/PD-L1\/VEGFA axis. Adv Sci (Weinh) 2024; 11(13): 2307242","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1203_CR98","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41392-023-01316-8","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Yan Y, Yin J, Tang N, Wang K, Huang L, Hu J, Feng Z, Gao Q, Huang A. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. Signal Transduct Target Ther 2023; 8(1): 63","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1203_CR99","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1158\/0008-5472.CAN-24-3196","volume":"85","author":"M Wang","year":"2025","unstructured":"Wang M, Zou F, Wang S, Yang Y, Xia C, Chen L, Liu B, Li L, Li MJ, Li H, Song W, Niu R, Yuan Z, Yang J, Li X, Chen K, Wu Z, Mi Z. CRTC2 forms co-condensates with YTHDF2 that enhance translational efficiency of m6A-modified mRNAs to drive hepatocarcinogenesis and lenvatinib resistance. Cancer Res 2025; 85(11): 2046\u20132066","journal-title":"Cancer Res"},{"issue":"1","key":"1203_CR100","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12943-020-01267-6","volume":"19","author":"J Li","year":"2020","unstructured":"Li J, Xie H, Ying Y, Chen H, Yan H, He L, Xu M, Xu X, Liang Z, Liu B, Wang X, Zheng X, Xie L. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer 2020; 19(1): 152","journal-title":"Mol Cancer"},{"issue":"16","key":"1203_CR101","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.7150\/thno.61178","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Pan C, Wang X, Xu D, Ma Y, Hu J, Chen P, Xiang Z, Rao Q, Han X. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics 2021; 11(16): 7640\u20137657","journal-title":"Theranostics"},{"issue":"1","key":"1203_CR102","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13046-024-03038-3","volume":"43","author":"P Yu","year":"2024","unstructured":"Yu P, Xu T, Ma W, Fang X, Bao Y, Xu C, Huang J, Sun Y, Li G. PRMT6-mediated transcriptional activation of ythdf2 promotes glioblastoma migration, invasion, and emt via the wnt-\u03b2-catenin pathway. J Exp Clin Cancer Res 2024; 43(1): 116","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1203_CR103","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13059-021-02308-z","volume":"22","author":"J Yu","year":"2021","unstructured":"Yu J, Chai P, Xie M, Ge S, Ruan J, Fan X, Jia R. Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma. Genome Biol 2021; 22(1): 85","journal-title":"Genome Biol"},{"issue":"1","key":"1203_CR104","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.gendis.2023.01.016","volume":"11","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Zhou K, Han L, Small A, Xue J, Huang H, Weng H, Su R, Tan B, Shen C, Li W, Zhao Z, Qing Y, Qin X, Wang K, Leung K, Boldin M, Chen CW, Ann D, Qian Z, Deng X, Chen J, Chen Z. RNA m6A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression. Genes Dis 2024; 11(1): 382\u2013396","journal-title":"Genes Dis"},{"issue":"17","key":"1203_CR105","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1182\/blood-2015-04-639062","volume":"126","author":"Z Li","year":"2015","unstructured":"Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood 2015; 126(17): 2005\u20132015","journal-title":"Blood"},{"issue":"2","key":"1203_CR106","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ccell.2015.12.011","volume":"29","author":"ER Lechman","year":"2016","unstructured":"Lechman ER, Gentner B, Ng SWK, Schoof EM, van Galen P, Kennedy JA, Nucera S, Ciceri F, Kaufmann KB, Takayama N, Dobson SM, Trotman-Grant A, Krivdova G, Elzinga J, Mitchell A, Nilsson B, Hermans KG, Eppert K, Marke R, Isserlin R, Voisin V, Bader GD, Zandstra PW, Golub TR, Ebert BL, Lu J, Minden M, Wang JC, Naldini L, Dick JE. miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell 2016; 29(2): 214\u2013228","journal-title":"Cancer Cell"},{"issue":"1","key":"1203_CR107","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1038\/s41467-021-26420-7","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Nguyen LXT, Chen YC, Wu D, Cook GJ, Hoang DH, Brewer CJ, He X, Dong H, Li S, Li M, Zhao D, Qi J, Hua WK, Cai Q, Carnahan E, Chen W, Wu X, Swiderski P, Rockne RC, Kortylewski M, Li L, Zhang B, Marcucci G, Kuo YH. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nat Commun 2021; 12(1): 6154","journal-title":"Nat Commun"},{"issue":"10","key":"1203_CR108","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s41388-022-02191-3","volume":"41","author":"Z Hua","year":"2022","unstructured":"Hua Z, Wei R, Guo M, Lin Z, Yu X, Li X, Gu C, Yang Y. YTHDF2 promotes multiple myeloma cell proliferation via STAT5A\/MAP2K2\/p-ERK axis. Oncogene 2022; 41(10): 1482\u20131491","journal-title":"Oncogene"},{"issue":"20","key":"1203_CR109","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41388-023-02675-w","volume":"42","author":"R Liu","year":"2023","unstructured":"Liu R, Miao J, Jia Y, Kong G, Hong F, Li F, Zhai M, Zhang R, Liu J, Xu X, Wang T, Liu H, Hu J, Yang Y, He A. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1\/p21cip1\/waf1\/CDK2-Cyclin E1 axis-mediated cell cycle transition. Oncogene 2023; 42(20): 1607\u20131619","journal-title":"Oncogene"},{"key":"1203_CR110","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.canlet.2018.11.006","volume":"442","author":"L Zhong","year":"2019","unstructured":"Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, Ma H, Kang T. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett 2019; 442: 252\u2013261","journal-title":"Cancer Lett"},{"key":"1203_CR111","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.tranon.2025.102395","volume":"56","author":"J Zheng","year":"2025","unstructured":"Zheng J, Liang Y, Xu X, Zhou J, Jiang S, Yu J. N6-methyladenosine binding protein YTHDF2 inhibits gastric cancer cell growth and predicts better prognosis in patients with gastric cancer. Transl Oncol 2025; 56: 102395","journal-title":"Transl Oncol"},{"issue":"1","key":"1203_CR112","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12575-023-00195-1","volume":"25","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Fan K, Dou N, Li L, Wang J, Chen J, Li Y, Gao Y. YTHDF2 exerts tumor-suppressor roles in gastric cancer via up-regulating PPP2CA independently of m6A modification. Biol Proced Online 2023; 25(1): 6","journal-title":"Biol Proced Online"},{"key":"1203_CR113","doi-asserted-by":"publisher","first-page":"592042","DOI":"10.3389\/fgene.2020.592042","volume":"11","author":"X Shen","year":"2021","unstructured":"Shen X, Zhao K, Xu L, Cheng G, Zhu J, Gan L, Wu Y, Zhuang Z. YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway. Front Genet 2021; 11: 592042","journal-title":"Front Genet"},{"issue":"1","key":"1203_CR114","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22(1): 329\u2013360","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1203_CR115","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12943-024-02097-6","volume":"23","author":"Z Yang","year":"2024","unstructured":"Yang Z, Wang X, Fu Y, Wu W, Hu Z, Lin Q, Peng W, Pan Y, Wang J, Chen J, Hu D, Zhou Z, Xu L, Zhang Y, Hou J, Chen M. YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment. Mol Cancer 2024; 23(1): 186","journal-title":"Mol Cancer"},{"issue":"6","key":"1203_CR116","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020; 9(6): 682\u2013720","journal-title":"Liver Cancer"},{"issue":"1","key":"1203_CR117","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","volume":"7","author":"DI Tsilimigras","year":"2021","unstructured":"Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D\u2019Angelica MI, Endo I, Parks RW, Doyle M, de Santiba\u00f1es E, Pawlik TM. Liver metastases. Nat Rev Dis Primers 2021; 7(1): 27","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1203_CR118","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1021\/jacsau.4c00754","volume":"5","author":"X Qiu","year":"2025","unstructured":"Qiu X, Kemker C, Goebel GL, Lampe P, Wallis N, Schiller D, Bigler K, Jiang M, Sievers S, Yeo GW, Wu P. Phenylpyrazoles as Inhibitors of the m6A RNA-Binding Protein YTHDF2. JACS Au 2025; 5(2): 618\u2013630","journal-title":"JACS Au"},{"issue":"9","key":"1203_CR119","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1039\/D4CB00105B","volume":"5","author":"CH Wang","year":"2024","unstructured":"Wang CH, Zhou H. Discovery of a new inhibitor for YTH domain-containing m6A RNA readers. RSC Chem Biol 2024; 5(9): 914\u2013923","journal-title":"RSC Chem Biol"},{"issue":"47","key":"1203_CR120","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1038\/s41388-024-03184-0","volume":"43","author":"H Xing","year":"2024","unstructured":"Xing H, Gu X, Liu Y, Xu L, He Y, Xue C. NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma. Oncogene 2024; 43(47): 3469\u20133482","journal-title":"Oncogene"},{"key":"1203_CR121","doi-asserted-by":"publisher","first-page":"111529","DOI":"10.1016\/j.cellsig.2024.111529","volume":"126","author":"N Lou","year":"2025","unstructured":"Lou N, Gu X, Fu L, Li J, Xue C. Significant roles of RNA 5-methylcytosine methylation in cancer. Cell Signal 2025; 126: 111529","journal-title":"Cell Signal"}],"container-title":["MedScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-026-1203-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:02:34Z","timestamp":1778137354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-026-1203-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1007\/s11684-026-1203-5","relation":{},"ISSN":["3091-4973","3091-4981"],"issn-type":[{"value":"3091-4973","type":"print"},{"value":"3091-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest\n                      Xin Liu, Sai Xiao, Songqi Duan, Jianjun Chen, and Shoubao Ma declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}